

The use of bladder instillations with hyaluronic acid in the management of young female patients with lower urinary tract symptoms and trigonitis

| | | |
|--|--|--|
| Submission date 17/03/2021 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| Registration date 12/05/2021 | Overall study status Completed | <input type="checkbox"/> Protocol |
| Last Edited 12/05/2021 | Condition category Urological and Genital Diseases | <input type="checkbox"/> Statistical analysis plan |
| | | <input type="checkbox"/> Results |
| | | <input type="checkbox"/> Individual participant data |
| | | <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Background and study aims

Trigonitis is inflammation of the trigone region of the bladder. Although trigonitis was first described more than a century ago and is a familiar term to urologists, it remains a poorly defined condition. The diagnosis is done during cystoscopy (camera inspection of the bladder) by the image of a white patch of tissue in the bladder trigone (the area between the bladder neck and the two ureteric openings). The precise underlying cause is still not well understood and its clinical significance continues to be unclear. Trigonitis has been traditionally associated with a wide range of lower urinary tract symptoms as well as with recurrent urinary tract infections. However, not all people with trigonitis have symptoms, and not all symptomatic patients have trigonitis, which complicates the understanding of this elusive disease process. The aim of this study is to find out whether the use of intravesical hyaluronic acid (treatment given directly into the bladder) in symptomatic women with trigonitis can improve their symptoms.

Who can participate?

Young women of reproductive age with persistent lower urinary tract symptoms and evidence of trigonitis on cystoscopy

What does the study involve?

All patients receive 10 weekly and 10 monthly treatment sessions of hyaluronic acid solution inside the bladder for a period of 1 year, which is known to repair the lining of the bladder wall. Their response to treatment is evaluated with symptom questionnaires. Each patient is assessed with a cystoscopy and biopsy (tissue sample) of trigonitis at the beginning and the end of the study.

What are the possible benefits and risks of participating?

Benefits include potential improvement of symptoms following treatment with hyaluronic acid. Risks include potential side effects from the drug which according to previous studies are very rare. Risks also include complications from bladder instillations such as a urinary infection and

also potential complications from cystoscopy and bladder biopsy performed before and after treatment such as bladder discomfort/pain, infection and bleeding.

Where is the study run from?

National and Kapodistrian University of Athens (Greece)

When is the study starting and how long is it expected to run for?

October 2009 to April 2017

Who is funding the study?

National and Kapodistrian University of Athens (Greece)

Who is the main contact?

Mr Marios Stavropoulos FEBU

Marios.Stavropoulos@addenbrookes.nhs.uk

Contact information

Type(s)

Scientific

Contact name

Mr Marios Stavropoulos

ORCID ID

<https://orcid.org/0000-0002-3908-9706>

Contact details

Newton 9A, Puddicombe Way

Cambridge Biomedical Campus

Cambridge

United Kingdom

CB2 0AB

+44 (0)7549862922

Marios.Stavropoulos@addenbrookes.nhs.uk

Type(s)

Public

Contact name

Mr Marios Stavropoulos

Contact details

Newton 9A, Puddicombe Way

Cambridge Biomedical Campus

Cambridge

United Kingdom

CB2 0AB

+44 (0)7549862922

stamarios@yahoo.gr

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

The use of intravesical hyaluronic acid in the management of symptomatic premenopausal women with pseudomembranous trigonitis

Study objectives

The use of intravesical hyaluronic acid in symptomatic women with trigonitis can improve their symptoms.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 13/11/2009, Sismanoglio Hospital Ethics Committee (Sismanogliou 1, Marousi 15126, Athens, Greece; +30 (0)2108039254; info@sismanoglio.gr), ref: 19750

Study design

Prospective non-randomized uncontrolled study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Treatment of lower urinary symptoms in women with trigonitis

Interventions

Intravesical administration of 40 mg/50 ml solution of sodium hyaluronate (Cystistat) once weekly for 10 weeks and once monthly for 10 months thereafter to all patients.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Cystistat (sodium hyaluronate)

Primary outcome measure

1. Pain and urgency measured using the visual analogue scale (VAS) at baseline, 10 weeks and 12 months
2. Further symptoms and quality of life measured using the Pain and Urgency/Frequency (PUF) symptom scale at baseline, 10 weeks and 12 months

Secondary outcome measures

Extent of trigonitis measured using cystoscopy and biopsy at baseline and end of treatment at 12 months

Overall study start date

08/10/2009

Completion date

02/04/2017

Eligibility

Key inclusion criteria

Women of reproductive age with lower urinary tract symptoms for at least 6 months and trigonitis seen on cystoscopy

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

30

Total final enrolment

Key exclusion criteria

1. Under 18 years
2. Pregnancy or breastfeeding
3. Radiation cystitis
4. Neurogenic bladder
5. Bladder cancer
6. Bladder stones
7. Stress incontinence
8. Urethral diverticulum
9. Pelvic organ prolapse
10. Uterine, vaginal or cervical cancers
11. Endometriosis

Date of first enrolment

07/01/2010

Date of final enrolment

04/02/2016

Locations**Countries of recruitment**

Greece

Study participating centre**Sismanoglio Hospital**

2nd Department of Urology

School of Medicine

University of Athens

Sismanogliou 1

Athens

Greece

151 26

Study participating centre**Attiko Hospital**

3rd Department of Urology

School of Medicine

University of Athens

Rimini 1

Athens

Greece

124 62

Sponsor information

Organisation

National and Kapodistrian University of Athens

Sponsor details

Department of Medicine

75 Mikras Asias str

Athens

Greece

115 27

+30 (0)210 746 2002 - 3

secr@med.uoa.gr

Sponsor type

University/education

Website

<http://en.uoa.gr/>

ROR

<https://ror.org/04gnjpq42>

Funder(s)

Funder type

University/education

Funder Name

National and Kapodistrian University of Athens

Alternative Name(s)

University of Athens

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

Greece

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

01/04/2021

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication

IPD sharing plan summary

Other